

FORM PTO-1390 (Modified) (REV 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 71745-56434	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/914149	
INTERNATIONAL APPLICATION NO. PCT/IB00/00219		INTERNATIONAL FILING DATE BC February 22, 2000		PRIORITY DATE CLAIMED FEBRUARY 22, 1999	
TITLE OF INVENTION TRANSLATION SYSTEM					
APPLICANT(S) FOR DO/EO/US Fatima Gebauer Giovanna Bergamini Matthias Hentze Davide Corona Peter Becker					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)). 11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). <p>Items 13 to 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15. <input type="checkbox"/> A FIRST preliminary amendment. 16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 17. <input type="checkbox"/> A substitute specification. 18. <input type="checkbox"/> A change of power of attorney and/or address letter. 19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail 23. <input checked="" type="checkbox"/> Other items or information: <p> PCT/RO/101 Request PCT/IPEA/401 PCT/IB/304 PCT/IPEA/402 PCT/IB/308 PCT/IPEA/408 </p>					

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 09/914149)		INTERNATIONAL APPLICATION NO. PCT/IB00/00219		ATTORNEY'S DOCKET NUMBER 71745-56434	
--	--	--	--	--	--

24. The following fees are submitted:.				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 <p style="text-align: center;">ENTER APPROPRIATE BASIC FEE AMOUNT =</p>				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than _____ months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30				\$130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	47 - 20 =	27	x \$18.00	\$486.00	
Independent claims	4 - 3 =	1	x \$80.00	\$80.00	
Multiple Dependent Claims (check if applicable). <input checked="" type="checkbox"/>				\$270.00	
TOTAL OF ABOVE CALCULATIONS =				\$1,826.00	
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				\$0.00	
SUBTOTAL =				\$1,826.00	
Processing fee of \$130.00 for furnishing the English translation later than _____ months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 +				\$0.00	
TOTAL NATIONAL FEE =				\$1,826.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$1,826.00	
				Amount to be:	\$
				refunded	\$
				charged	\$

a. ☒ A check in the amount of **\$1,826.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.


c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **04-1105** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David G. Conlin (Reg. No. 27026)
 Dike, Bronstein, Roberts & Cushman
 Intellectual Property Practice Group
 Edwards & Angell
 P.O. Box 9169
 Boston, MA 02209
 Tel: (617) 439-4444


 SIGNATURE
 David G. Conlin
 NAME
 27026
 REGISTRATION NUMBER
 August 22, 2001
 DATE

TRANSLATION SYSTEM

The present invention relates to a cell-free translation system. In particular, the invention relates to a cell-free translation system derived from cell extracts, that reproduces the synergism that occurs during translation *in vivo* between the *cap* and the
5 *poly(A)* tail structures of the mRNA.

Translational control is an important mechanism for the regulation of gene expression during a variety of biological processes, including cellular metabolism (Hentze & Kuhn, (1996) P.N.A.S. USA 93: 8175-8182), cell differentiation (Ostareck *et al.*, 1997, Cell. 89: 597-606) and embryonic development (Wickens *et al.*, 1996, in Translation Control,
10 Eds. Hershey, J.W.B., Mathews, M.B. and Sonenberg, N. (Cold Spring Harbour Lab. Press, Plainview, NY, pp. 411-450). Failure to regulate translation properly often leads to disease.

In vivo, two modifications in the mRNA, namely a *cap* structure at the 5' end and a *poly(A)* tail at the 3' end, act synergistically to promote mRNA translation (Gallie, 1991,
15 Genes Dev. 5: 2108-2116). To date, research into the function of those structures and the synergism that occurs between them has been restricted by the lack of *in vitro* systems that accurately recapitulate these features.

Recently, a cell-free translation system that reproduces this synergism has been obtained from the unicellular eukaryote *Saccharomyces cerevisiae* (Iizuka *et al.*, 1994,
20 Mol. Cell. Biol. 17: 7322-7330). Capped mRNAs were found to be translated 50-fold more efficiently than uncapped mRNAs in yeast lysate. Polyadenylated RNAs were found to be translated 140-fold more efficiently than non-polyadenylated RNAs. mRNAs containing both a 5' *cap* and a 3' *poly(A)* tail were found to be translated several hundred-fold more efficiently than mRNAs lacking both of these terminal sequences.

25 A cell-free translation system derived from animal cells that is capable of reproducing this synergism would be of great value for a number of reasons. Firstly, this would facilitate and enhance the validity of basic research into the factors and mechanisms involved in translational control in higher eukaryotes, including the regulation of translation by *cis*- and *trans*- acting factors, the molecular basis of synergism, mRNA

stability and polyadenylation. Second, species-specific differences in translational mechanisms could be evaluated. Such a system would also allow the improvement of large-scale protein synthesis, both with respect to the efficiency of translation and to the fidelity of post-translational modification.

5 Summary of the Invention

According to a first aspect of the present invention, there is provided a method for the *in vitro* translation of a ribonucleic acid template, said ribonucleic acid having both a 5' cap and a 3' poly A tail, said method comprising incubating a cell extract of a multicellular eukaryote with said ribonucleic acid template under conditions such that translation of the RNA template to produce its encoded protein by one or more components in the cell extract occurs and the amount of the encoded protein thus produced is greater than the total of (a) the amount of the encoded protein that is produced under said conditions when the ribonucleic acid template has a 5' cap but no 3' poly A tail, plus (b) the amount of the encoded protein that is produced under said conditions when the ribonucleic acid template has a 3' poly A tail but no 5' cap.

It has been found, surprisingly, that by combining a dechoriation procedure that has been previously used for the study of chromatin assembly (Becker *et al.*, 1994) with homogenisation and centrifugation conditions used to study translation (Scott *et al.*, 1979) a protocol results that allows the preparation of cell extract with greatly improved properties over conventionally known extracts for use in *in vitro* translation procedures.

The cell extract may be an animal cell extract, such as a mammalian cell, or an insect cell. Specific examples include cell extracts of *Drosophila*, *C. elegans*, rodent, rabbit (for example, reticulocyte cells), human (for example HeLa cells) and primate cells. The cells may be embryonic or adult or from a particular tissue such as the ovaries. Preferably, the cell extract is a *Drosophila* cell extract, most preferably a *Drosophila* embryo or ovary cell extract.

The extract exhibits properties that were previously unforeseen, such as the capability to reproduce the synergism that occurs during translation *in vivo* between the cap and the poly(A) tail structures of an mRNA molecule, and the capability to perform mRNA polyadenylation. In addition, the procedure is simple and allows the preparation of large

amounts of extract at low cost. This makes the system useful in both basic research and in commercial applications as is discussed in more detail below.

RNA templates suitable for use in the methods of *in vitro* translation of the invention
5 may be recombinant or can be purified native templates. In preferred aspects of the invention, the poly(A) tail of the RNA template can be encoded in a DNA coding sequence which can be transcribed to generate an RNA template with a poly(A) tail of defined length. An alternative method of generating the poly(A) tail is the use of a poly(A) polymerase in an *in vitro* reaction to add the tail to the template as a post-
10 transcriptional modification.

The 5' cap portion may be added co-transcriptionally to the RNA template by the RNA polymerase. A suitable protocol can be found in "Protocol and Applications Guide"; Promega, 2nd edition, p62. If the template is a purified native RNA template, the cap
15 structure will already be in place.

According to a second aspect of the invention there is provided a method for the preparation of a *Drosophila* embryo extract comprising the steps of a) dechorionating *Drosophila* embryos in an aqueous isotonic buffer comprising detergent and bleach; b)
20 washing the embryos; c) homogenizing the embryos to produce a homogenate; d) centrifuging the homogenate; and e) recovering non-pelleted material from the centrifuged homogenate. This cell extract is particularly suited for use in the method of the first aspect of the invention.

The age of the embryo is not crucial to the method of the invention, although embryos
25 of between the ages of 1 hour and 12 hours of development are preferred.

Before preparation of extract, the embryos should preferably be collected in a sieve and washed extensively with water to remove debris from the culture medium in which they have been laid. For preparation of extract, the embryos are washed with an aqueous buffer, preferably with fresh EW buffer (0.7% NaCl, 0.04% Triton X-100), and poured
30 into a suitable vessel. An excess of buffer is then added and the embryos allowed to settle. At this stage, floating embryos should be discarded. For dechoriation, fresh buffer should be added and the embryo suspension agitated, preferably using a spinning

magnet or other suitable device. In all steps for the preparation of cell extract, ethanol-based buffers should be avoided.

For dechoriation, bleach is added to the embryo suspension, preferably at a concentration of about 3% by volume and the solution incubated for an appropriate
5 time. Preferably, incubation is for between 1 and 9 minutes, most preferably 3 minutes.

Dechoriation may be carried out at a temperature of between 18 and 37°C. Preferably, dechoriation is carried out at about 25°C.

After dechoriation, embryos are preferably transferred to a sieve and washed extensively with water. Dechorionated embryos are then transferred to a suitable vessel
10 (such as a beaker or cylinder) and buffer such as DE buffer (10mM HEPES pH 7.4, 5mM DTT) added. Floating embryos are discarded. Preferably, about 1 volume (with respect to the volume of settled embryos) of fresh buffer containing protease inhibitors is added to prevent proteolysis of components of the extract.

Embryos are then homogenised. Preferably, homogenisation is carried out at about 4°C.
15 Most preferably, a Potter-Elvehjem homogeniser is used at about 1500 rpm (about 20 strokes). The homogenate should preferably be kept on ice to minimise proteolysis.

The homogenate is preferably centrifuged, ideally in an ultracentrifuge at 24,000 rpm (40,000g)/TLS-55 rotor/4°C/20 minutes. The clear interphase is taken, ideally by puncturing the tube with a syringe, and is transferred to a Falcon tube.

20 Glycerol may then be added to the extract, preferably to a 10% final concentration, and the extract aliquoted, frozen in liquid nitrogen and kept at -70°C for future use.

Drosophila ovaries may also be used to produce a cell extract. The procedure is as follows: adult female flies are manually dissected to obtain the ovaries, which should be placed in an eppendorf tube on ice in an aqueous medium, for example PBS. Ovaries
25 are then allowed to settle, before transferring the ovaries slowly from an isotonic medium to a hypotonic medium. For example, the ovaries can be washed twice with around 12 volumes of a 1:1 mix of PBS:DEI buffer (DEI = 10mM HEPES pH 7.4, 5mM DTT, 1 x COMPLETE-Protease inhibitors from Boehringer Mannheim cat#1697498), and twice with 12 volumes of DEI. After washing, all the buffer is

removed and the ovaries manually homogenised using a plastic pestle. The homogenate can then be spun and the extract collected as described above for embryo extract.

- The invention also provides a method for the preparation of a mammalian cell extract comprising the steps of a) collecting cells by centrifugation; b) washing the cells; c) resuspending the cells; d) homogenising the cells to produce a homogenate; e) centrifuging the homogenate and f) recovering non-pelleted material from the centrifuged homogenate. This cell extract is well-suited to use in the method of the first aspect of the invention.

- Before preparation of extract, the cells should be grown in culture, preferably at exponential growth. Suspension cultures grown in, for example Jocklik's medium supplemented with 5% newborn bovine serum at 37°C, are suitable. The cells may be collected from culture by centrifugation, for example, by harvesting at 700g for 15 minutes. For preparation of extract, the cells should be washed with phosphate buffered saline at 4°C, before resuspension in a suitable ice cold hypotonic buffer such as a buffer containing containing Hepes 10 mM. PH 7.6. KOAc 10 mM. Mg(OAc)₂ 0.5 mM and Dithiothreitol 5 mM. Reduced amounts of DTT are not recommended and addition of protease inhibitors is optional.

- After a short period on ice, for between 2 and 10 minutes, the cells are homogenised. Preferably, homogenisation is carried out at about 4°C. Most preferably, the cells are homogenised using between 10 and 30 strokes of a Dounce homogeniser (pestle type B). The homogenate should preferably be kept on ice to avoid proteolysis.

The homogenate is then centrifuged, ideally at 14000g for 5 minutes at 4°C. A longer centrifugation is not recommended. Supernatant fluid is divided into aliquots frozen in liquid nitrogen and stored at -80° C. Addition of glycerol is not necessary.

- According to a third aspect of the invention there is provided the extract of *Drosophila* embryos or ovaries, or of mammalian cells, produced according to the methods of the second aspect of the invention.

According to a fourth aspect of the invention there is provided a method for the *in vitro* translation of a ribonucleic acid template, comprising the steps of adding a ribonucleic

acid template to a translation mix in the presence of the embryo, ovary or mammalian cell extract of the third aspect of the invention to form a reaction mix and incubating the reaction mix for at least 90 minutes at between 18°C and 28°C. Preferably, the reaction mix is incubated for at least 90 minutes at 25°C.

- 5 By reaction mix is meant a solution of components necessary for *in vitro* translation to occur. Such components may include any of the following: spermidine, amino acids, creatine phosphate, creatine kinase, dithiothreitol (DTT), buffer, $\text{Mg}(\text{OAc})_2$, KOAc, tRNA, cell extract and RNA template. This reaction mix should preferably be prepared fresh. All the components of the reaction mix, except the creatine kinase, should be
0 dissolved in distilled water to their required concentrations.

Preferably, the buffer is HEPES buffer, although any buffer with a low concentration of salt (below 10mM) may be used. HEPES buffer is most preferably used at a final concentration of between 16 and 24mM. As used herein, the term "final concentration" means the concentration of the component that is present in the *in vitro* translation mix.

- 5 These concentrations are optimal for the translation reaction to take place.

Preferably, said tRNA is calf liver tRNA, at a final concentration of below 150µg/ml, most preferably about 100µg/ml.

- For *Drosophila* ovary or embryo extract, the final concentration of spermidine is preferably about 0.1mM. For amino acids, final concentration is about 60µM. For
!0 creatine phosphate, the concentration can be in the range 17-23mM. It is shown herein (see Figure 6) that it is preferable to use fresh or newly thawed creatine phosphate. The level of translation doubles when fresh creatine phosphate is used. Creatine kinase should be used at a concentration of about 0.08mg/ml.

- The concentrations of DTT, $\text{Mg}(\text{OAc})_2$ and KOAc should be optimised for each
!5 individual mRNA template, as will be appreciated by those skilled in the art. For example, for translation of M1414WT (bgal) (see below), ideal concentrations are DTT, 1.2mM; $\text{Mg}(\text{OAc})_2$, 0.6mM; and KOAc, 60mM. For c-Luc-a, ideal concentrations are DTT, 0mM; $\text{Mg}(\text{OAc})_2$, 0.4mM; and KOAc, 30mM.

05034449.121904

However, final concentration of $\text{Mg}(\text{OAc})_2$ can be in the range 0-3mM. KOAc can range between 0 and 200mM. DTT can range between 0-4mM.

Embryo or ovary extract should preferably be used at a concentration of about 40% by volume.

- 5 For mammalian cell extract, the final concentration of spermidine is preferably about 0.1mM. For amino acids, final concentration is about 100 μ M. For creatine phosphate, the concentration can be in the range 17-23mM. Creatine kinase should be used at a concentration of about 0.05mg/ml. As stated above for *Drosophila* extract, the concentrations of $\text{Mg}(\text{OAc})_2$ and KOAc should be optimised for each individual mRNA
- 10 template, as will be appreciated by those skilled in the art. For example, suitable concentrations may be along the following lines; $\text{Mg}(\text{OAc})_2$, 2.5mM; KOAc, 50mM.

However, final concentration of $\text{Mg}(\text{OAc})_2$ can be in the range 0-3mM. KOAc can range between 0 and 200mM. DTT can range between 0-4mM.

- Mammalian cell extract should preferably be used at a concentration of about 40% by
- 15 volume.

- Optimal RNA template concentration will vary depending upon the RNA type. The skilled artisan will appreciate that optimisation of the system may be easily performed for a particular RNA species of choice using routine procedures. For example, for the species c-luc-a (coding for firefly luciferase) a concentration of about 3.2ng/ μ l is
- 20 optimal using *Drosophila* embryo extract. The mRNA template should preferably be capped and should contain a *poly(A)* tail of more than 31 adenine nucleotides (more preferably 70-100 adenines).

- For each mRNA species, preliminary reactions should be performed so as to obtain a curve of translation efficiency with differing amounts of mRNA. An amount of mRNA
- 25 should be used in the linear range of translation. In the examples described herein, test reactions were performed with M1414WT (bgal) [this codes for the β -galactosidase enzyme and contains 5' and 3' UTR sequences from *Drosophila oskar* mRNA], c-Luc-a and Luc mRNA (Promega).

Reaction mix prepared in this fashion contributes to the advantageous features of the method of this aspect of the invention, namely reproducing the synergy between the 5' *cap* and 3' *poly(A)* tail of the RNA molecule for translation.

- 5 Additionally to this synergy, the level of translation is enhanced, so leading to a greater production of protein. The fidelity of post-translational modification appears also to be retained, differentiating the system of the present invention over that described previously in yeast (Iizuka *et al.*, 1994). Although yeasts do possess enzymes that are capable of effecting the post-translational modification of proteins, the type and extent of modification tends to differ from that found in higher eukaryotes. Consequently, the
- 10 *Drosophila* system of the present invention generates proteins modified similarly to the state in which they are found *in vivo*.

The incubation step is preferably performed for sufficient time to allow the translation reaction to proceed to the extent desired. Preferably, the incubation step is performed for at least about 90 minutes.

- 15 Ranges of suitable concentrations of components of the reaction mix for *Drosophila* extract, along with optimal concentrations, are given below in Table 1. These concentrations were optimised for luc and c-luc-a mRNA species, coding for the firefly luciferase enzyme.

TABLE 1

	Range tested	Optimal	RNA	Observations
Creatine phosphate	0-168mM	17-23mM	Luc	Use fresh (thaw only once)
Creatine kinase	0-1.68 mg/ml	0.08 mg/ml	Luc	
KOAc	0-200mM	74mM	Luc	Should be optimised for each RNA template
Mg(OAc) ₂	0-3mM	0.3mM	Luc	Should be optimised for each RNA template

Spermidine	0-1.8mM	0.1mM	c-Luc-a	
Amino acids	0-100 μ M	60 μ M	c-Luc-a	
DTT	0-4mM	0mM	c-Luc-a	Should be optimised for each RNA template
tRNA	0-150 μ g/ml	100 μ g/ml	Luc	
Temperature	18-37°C	25°C	c-Luc-a	

Ideally, the *in vitro* translation reaction is performed in a final volume of about 12.5 microlitres. Below, in Table 2, the volume of stock concentrations is given in order to make up a reaction volume of 12.5 microlitres.

5 TABLE 2

- Final volume = 12.5 μ l
- Mix per reaction:

	Volume (μ l)	Final conc.
2.5mM spermidine	0.5	0.1mM
1mM amino acids (Promega)	0.75	60 μ M
1 M creatine phosphate (fresh or newly thawed)	0.21	16.8mM
10 μ g/ μ l creatine kinase	0.1	80 ng/ μ l
0.1 M DTT	0.15	1.2mM
1 M HEPES pH 7.4	0.3	24mM
4.13mM Mg(OAc) ₂	1.8	0.6mM

1 M KOAc	0.75	60mM
1.1 $\mu\text{g}/\mu\text{l}$ calf liver tRNA	1.1	100ng/ μl
Embryo extract	5	40%
RNA template	1	3.2ng/ μl
H ₂ O	to 12.5 μl final	

For HeLa cell extract, the reaction mix may be as follows:

Untreated extract	40% of the final volume
Hepes buffer, pH 7.6	16 mM
KOAc	50 mM
Mg(Oac) ₂	2.5 mM
amino acid mixture	100 μM
spermidine	0.1 mM
ATP	0.8 mM
GTP	0.1 mM
Creatine phosphate	20 μM
Creatine kinase	50 ng/ μl
Calf liver tRNA	100 ng/ μl
RNA template	1 ng/ μl

These optimal values were obtained for this translation assay by testing a range of components concentrations with a capped and polyadenylated mRNA expressing the bacterial enzyme chloramphenicol acetyltransferase (CAT). The amount of the CAT

protein produced was measured using a colorimetric enzyme immunoassay (CAT ELISA, Böhringer Mannheim).

According to a fifth aspect of the invention there is provided the use of cell extract according to the third aspect of the invention in a method of *in vitro* translation of a
5 ribonucleic acid template, such as the methods of the first and fourth aspects of the invention. The method reproduces the synergism exhibited *in vivo* between the 5' *cap* and 3' *poly(A)* tail of the ribonucleic acid template.

According to a sixth aspect of the invention there is provided the use of cell extract according to the third aspect of the invention or method of first or the fourth aspects of
10 the invention to screen for compounds that either a) decrease the translation, polyadenylation and/or stability of all mRNA species, or of specific mRNAs; b) potentiate the translation, polyadenylation and/or stability of all mRNA species, or of specific mRNAs; or c) decrease or potentiate the synergism between the 5' *cap* and the 3' *poly(A)* tail of the mRNA. Suitable compounds may interact (either directly or
15 indirectly) with only one of the 5' *cap* or *poly(A)* structures. Preferably, compounds identified in such a screen have an effect on translational control in higher eukaryotes, in particular insects. This screening method has advantages over prior art methods because the synergy exhibited between *cap* and *poly(A)* structures mimics the features of *in vivo* translation and allows the screening in an *in vitro* system for modifiers
20 effecting translation that are significantly more likely to function *in vivo*.

According to a seventh aspect of the invention there is provided a compound identified by a screen according to the sixth aspect of the invention. Suitable compounds may be natural or synthetic, for example, an aptamer, or a peptide and may be useful for therapy of diseases and for the control of plagues and diseases caused by insects, for example
25 malaria and plant pestilence. For example, the compound may that interact with 5' *cap* or 3' *poly(A)* structures of an mRNA template or affect in some way the synergism between the 5' *cap* and 3' *poly (A)* tail of an mRNA template. In some instances, compounds may be specific for a certain group of mRNA templates, or for mRNA templates within a certain species. It is envisaged that such compounds will prove
30 useful in the control of plagues and diseases caused by insects, for example malaria and plant pestilence, by interfering with the expression of certain essential insect proteins.

According to an eighth aspect of the invention there is provided the use of the cell extract according to the third aspect of the invention or method of the first or fourth aspects of the invention in research into the regulation and function of post-transcriptional mRNA modification or post-translational protein modification.

- 5 After the identification of the polypeptides that are responsible for the synergism between the 5' cap and the 3' poly(A) structures of the mRNA, it is possible to study the productive interactions between them and to define the domains and amino acid residues that are responsible for these interactions. It will, then, become possible to design chimeric molecules that comprise the effector domains from these polypeptides
- 10 fused to other polypeptides of interest. Upon interaction of the polypeptides of interest, the effector domains would promote the translation of a reporter mRNA, such as luciferase. The level or degree of interaction would be quantified by measuring the amount of light that is produced. In order to aid the study of interactions of interest, appropriate components such as *Drosophila* embryo extract or HeLa cell extract,
- 15 reporter mRNA and reaction mix may be provided in the form of a kit.

According to a ninth aspect of the invention there is provided a kit for the analysis of *in vitro* translation, polyadenylation and/or stability of ribonucleic acid. The kit should contain cell extract according to the third aspect of the invention along with stock solutions of all the other components of the translation mix in appropriate quantities.

- 20 The kit will therefore in addition comprise any one or all of spermidine, amino acids, creatine phosphate, creatine kinase, optionally dithiothreitol (DTT), buffer, $\text{Mg}(\text{OAc})_2$, KOAc, tRNA, and RNA template.

- As noted above, preferably, the buffer is HEPES buffer, the tRNA is calf liver tRNA and ideally, the creatine phosphate is made fresh. However, creatine phosphate may be
- 25 supplied in powdered form in the kit for dissolution in distilled water as and when required for use.

- Generally, an RNA template will not be supplied as part of the kit, since in the main part, it is envisaged that the kit will be purchased for the purposes of experimental research. However, a control RNA template may be included in the kit so that a user can
- 30 ensure that the translation reaction is proceeding appropriately. For example,

comparison with a control RNA template may be used to optimise the concentration of test RNA, DTT, $\text{Mg}(\text{OAc})_2$ and KOAc that is to be used.

The kit preferably also contains appropriate instructions to enable a user to perform the *in vitro* translation reaction appropriately.

- 5 The invention will now be described in detail with particular reference to a Luc mRNA template. As will be clear to the person of skill in the art, variations from the described protocol may be made without departing from the scope of the invention.

All references cited herein are hereby incorporated by reference in their entireties.

BRIEF DESCRIPTION OF THE FIGURES

- 10 Figure 1 shows comparative results of translation levels and levels of synergy found between 5' *cap* and 3' *poly(A)* tail of an RNA template.

Figure 2 is an expanded scale of the results of Figure 1.

Figure 3 shows optimisation of Mg^{2+} concentration.

Figure 4 shows optimisation of K^+ concentration.

- 15 Figure 5 shows optimisation of creatine kinase concentration.

Figure 6 shows how percentage translation is improved by using fresh creatine phosphate.

Figure 7 shows optimisation of creatine phosphate concentration.

Figure 8 shows optimisation of spermidine concentration.

- 20 Figure 9 shows optimisation of tRNA concentration.

Figure 10 shows optimisation of temperature, amino acid concentration and DTT concentration using c-luc-a RNA.

Figure 11 shows the time course of translation of CAT mRNAs using the HeLa cell extract.

Figure 12 shows Northern blot analysis of the transcripts during the translation assay. Bars represent radioactive intensity of each messenger measured by a phosphoimager. Graph (A) shows the four messengers at different times, from 0 to 150 minutes. Graph (B) shows the Cap and the Cap-pA transcripts from 0 to 90 min.

- 5 Figure 13 shows time course of translation of the Luc messengers. Efficiency of translation is represented by light emission measured by a luminometer. Graph (B) shows the data represented in Graph (A) with the y axis maximum at 20000 luminescence instead of 550000.

EXAMPLES

10 Example 1: Preparation of extracts from *Drosophila* embryos

Extracts from 1h30', 3h, 6h and 12h embryos were prepared with similar results.

- Embryos were laid by 2-3 day old adult *Drosophila* flies on agar-apple juice plates (2.9% Agar; 30% Apple Juice; 4.4% Rubensirup; 0.25% Nipagin). The plates, spread with some fly food (220ml deionized water, 1.4ml Propionic acid; 150g dry yeast), were
- 15 left overnight for embryo laying). Embryos from 16 agar-apple juice plates were collected in a pile of sieves (the first with a cut-off size of an adult fly, the second with a cut-off size of a fly appendix [e.g.: a leg, a head or an antenna], the last with a cut-off size of a single embryo) and washed extensively (~5-10 minutes) with tap water to remove debris coming from the plates.
- 20 Embryos were subsequently washed with freshly prepared isotonic EW buffer (0.7% NaCl, 0.04% TritonX-100). To do this, embryos were transferred to a 500ml cylinder containing EW buffer, and were allowed to settle for ~3-5 minutes (roughly the time needed for 90% of the embryos to pellet by gravity) and were then washed twice with 500ml EW Buffer. Floating embryos were eliminated by suction.
- 25 Embryos were dechorionated in the 500 ml cylinder at room temperature (~20-25°C) with 260ml of EWB (0.7% NaCl, 0.04% TritonX-100, 3% Sodium Hypochlorite) for 3 minutes under vigorous agitation provided by a magnetic stirrer. Sodium Hypochlorite was from Sigma, Thomas Chemikalien, or U.S. CHLOROX. No significant change in the translation efficiency of the extract was noted for different bleach types.

- Dechorionated embryos were transferred back to the sieves, and were vigorously and extensively washed with tap water (by flushing a strong stream of water for about 5-10 minutes). Washed embryos were settled by gravity twice with 100 ml of DE buffer (10mM HEPES pH 7.4, 5mM DTT) in a 100ml cylinder. Floating embryos were discarded, and an equivalent of one volume (with respect to the settled embryos) of DEI buffer (10mM HEPES pH 7.4, 5mM DTT, 1x COMPLETE-Protease Inhibitors from Boehringer Mannheim cat# 1697498) was added.

- Embryos in DEI buffer were homogenised in a cold room (~4°C) by 20 strokes of a Potter-Elvehjem homogeniser at 1500 rpm and the homogenate was kept on ice. The homogenate was spun in a table-top ultracentrifuge (Beckmann) at 24000 rpm (40000x g) in a TLS-55 rotor at 4 C for 20 minutes. The clear aqueous interphase was taken by puncturing the tube with a syringe, and was transferred to a Falcon tube. Glycerol was added to 10% final, and the extract was aliquoted, flash-frozen in liquid nitrogen and stored at -70°C.

15 Example 2:

2.1 *In vitro* translation

A typical experiment is shown below.

The reaction is performed in a final volume of 12.5 µl, containing the following mix (a):

20		<u>volume (µl)</u>	<u>Final conc.</u>	
	2.5 mM spermidine	0.5	0.1 mM	
	1mM amino acids	0.75	60 µM	
	1 M creatine phosphate (fresh or newly thawed)	0.21	16.8 mM	
25	10 µg/µl creatine Kinase	0.1	80 ng/µl	
	0.1 M DTT	Y	0 - 1.2 mM	(b) (*)
	1 M HEPES pH 7.4	0.3	24 mM	
	4.13 mM Mg(OAc) ₂	Z	0.3 - 0.6 mM	(b) (*)
	1 M KOAc	W	30 - 80 mM	(b) (*)
30	1.1 µg/µl calf liver tRNA	1.14	100 ng/µl	

embryo extract	5	40%
RNA template	X	(c)
H ₂ O	to 12.5 µl final	

The reaction was incubated at 25°C for 90 min.

- 5 (a) A master mix should be prepared for as many samples as it is required.

(b) Should be optimised for each mRNA template.

- (c) The mRNA template should be capped and should contain a poly(A) tail of more than 31 A's (usually 70-100 A's), although mRNAs without a poly(A) tail are also translated albeit at lower efficiency. A curve of translation with different amounts of
10 RNA should be performed to use an amount in the linear range of translation.

(*) Concentrations (mM) optimal for:

	<u>RNA</u>	<u>DTT</u>	<u>Mg(OAc)₂</u>	<u>KOAc</u>
	M1414WT (bgal)	1.2	0.6	60
	c-Luc-a	0	0.4	30
15	mLuc-a	0	0.6	80
	c-CAT-a	1.2	0.6	60

- M1414WT* RNA encodes for the β-galactosidase enzyme (bgal) and contains 5' and 3' UTR sequences from *Drosophila oskar* mRNA. *c-Luc-a* encodes for the firefly luciferase enzyme. *mLuc-a* encodes for the firefly luciferase enzyme, and contains the
!0 5' UTR of *Drosophila msl-2* mRNA. *c-CAT-a* encodes for the chloramphenicol acetyl transferase enzyme. All RNAs are capped and polyadenylated.

Spermidine is from SIGMA, cat# S-0381.

Amino acids were obtained from Promega (cat #L4461), or can be self-made from a SIGMA kit (cat# LAA-21).

- !5 Creatine Kinase is from Boehringer Mannheim (cat# 126969). The stock solution is prepared at 10 mg/ml in 50% glycerol, 20 mM HEPES-KOH pH 7.4.

Using this protocol, together with the extract described in Example 1, high levels of translation and synergy can be obtained, compared to other methods (see Figure 1).

2.2 Optimisations

Ranges of suitable concentrations, along with optimal concentrations, are given below.

- 5 The method of Example 1 was followed (not that of Scott *et al*), and one concentration value was varied for each experiment. Luc RNA from Promega was used for these experiments, except where otherwise stated.

Figure 3 shows optimisation of Mg^{2+} concentration. Optimum concentration was found to be 0.3mM. Figure 4 shows optimisation of K^{+} concentration. Optimum concentration
10 was found to be 74mM for this system.

Figure 5 shows optimisation of creatine kinase concentration. Optimum concentration was found to be 0.08mg/ml for this system.

Figure 6 shows how % translation could be improved more than two times by using fresh creatine phosphate.

- 15 Figure 7 shows optimisation of creatine phosphate concentration. Optimum concentration was found to be 23mM for this system.

Figure 8 shows optimisation of spermidine concentration. Optimum concentration was found to be 0.1mM for the c-luc-a RNA system.

- Figure 9 shows optimisation of tRNA concentration. Optimum concentration was found
20 to be 100 μ g/ml for the luc RNA system.

Figure 10 shows optimisation of temperature, amino acid concentration and DTT concentration using c-luc-a RNA. Optimum temperature was found to be 25°C. Optimum amino acids concentration was found to be 60 μ M. Optimum DTT concentration was found to be 0mM.

	<u>Range tested</u>	<u>Optimal</u>	<u>RNA</u>	<u>Observations</u>
Creatine phosphate	0 - 168 mM	17 - 23 mM	Luc	Use fresh (thaw only once)
Creatine kinase	0 - 1.68 mg/ml	0.08 mg/ml	Luc	
KOAc	0 - 200 mM	74 mM	Luc	Should be optimised for each RNA template
Mg(OAc) ₂	0 - 3 mM	0.3 mM		
Spermidine	0 - 1.8 mM	0.1 mM	c-Luc-a	0.3 mM or no spermidine also works for some mRNAs
amino acids	0 - 100 μ M	60 μ M	c-Luc-a	
DTT	0 - 4 mM	0 mM	c-Luc-a	Should be optimised for each RNA template
tRNA	0 - 150 μ g/ml	100 μ g/ml	Luc	
Temperature	18 - 37°C	25 °C	c-Luc-a	

Example 3: Comparison between method of the invention and that described in Scott *et al.*, (1979) *Biochemistry*, 18(8): 1588-1594.

5 Drosophila embryo extracts were prepared in parallel either according to the method described in Scott *et al.* (1979) or to the method of the invention. These extracts were assayed for translation using either the conditions described in Scott *et al.* (1979) or the conditions described above.

10 Briefly, the Scott protocol consisted in dechorionating the embryos in a solution of 50% ethanol/50% chlorox for 1 m in under agitation, washing the embryos 5 times in PBS after dechorionation using a table-top centrifuge at top speed to obtain the embryo pellet and homogenising the embryo pellet in 10mM HEPES pH7.4, 6mM β -mercaptoethanol.

The extracts obtained using this method were used in an *in vitro* translation reaction using either the conditions described in Example 2.1, those described by Scott *et al.* (1979) or those described by Scott with an increased time of translation. The RNA used

for translation encoded the firefly luciferase and contained either a cap (c), a poly(A) (a), or both (c-a). The results (Figures 1 and 2) indicate that by using our extract in our *in vitro* translation conditions a high degree of translation and synergism was obtained. When the Scott extract was used under Scott's *in vitro* translation conditions, no synergism was obtained and a very low level of translation was observed. Using combination of both extracts with either ours or Scott's *in vitro* translation conditions, low levels of translation with various degrees of synergy were obtained. Any apparent synergy in this figure exhibited by the Scott extract using our conditions is believed only to be because the very low level of translation seen gives unreliably low levels of luciferase activity. Accordingly, the (c), (a) and (c-a) figures cannot be compared. These data indicate that the combination of our extract (Example 1) with our *in vitro* translation conditions (Example 2.1) make possible a high degree of translation and synergism.

Comparative results of translation levels and levels of synergy found between the 5' cap and the 3' poly(A) tail of the mRNA template are shown in Figures 1 and 2.

Translation levels using the Scott method were very low. Translation levels using the extract and method of the invention were high and the level of synergy noted was also high (12x and 15x). Figure 2 shows the results of Figure 1 on an expanded scale.

Example 4: Preparation of cell-free extracts from HeLa cells

HeLa cells were maintained at exponential growth in suspension cultures at 37° C in Jocklik's Medium supplemented with 5% newborn bovine serum. Approximately 204 litres of cells at densities of $3-6 \times 10^5$ cells/ml were harvested by centrifugation at 700 g for 15 minutes and washed three times with phosphate buffered saline (PBS) at 4° C.

Pelleted cells were resuspended in 1 volume of ice-cold hypotonic buffer containing Hepes 10 mM, pH 7.6; KOAc 10 mM; $Mg(OAc)_2$ 0.5 mM; and Dithiothreitol 5 mM. Reduced amounts of DTT are not recommended and addition of protease inhibitors is optional.

After 2-10 minutes on ice, cells were broken with 10-30 strokes of a tight-fitting Dounce homogeniser (pestle type B).

Cell lysates were centrifuged at 14,000 g for 5 minutes (a longer centrifugation is not recommended) at 4° C. Supernatant fluid was divided into aliquots frozen in liquid nitrogen and stored at -80° C. Addition of glycerol is not necessary.

Example 5: In vitro translation assay

- 5 Incubation mixtures contain:
 - untreated extract 40% of the final volume
 - Hepes buffer, pH 7.6 16 mM (+4 mM of the lysate)
 - KOAc 50 mM (+4 mM of the lysate)
 - Mg(Oac)₂ 2.5 mM (+0.2 mM of the lysate)
- 10
 - amino acid mixture 100 µM
 - spermidine 0.1 mM
 - ATP 0.8 mM
 - GTP 0.1 mM
 - Creatine phosphate 20 µM
- 15
 - Creatine kinase 50 ng/µl
 - Calf liver tRNA 100 ng/µl
 - RNA template 1 ng/µl

Reaction mixtures, typically at a final volume of 12.5µl were incubated at 37° C for 90 minutes.

- 20 In order to obtain these optimal values for the translation assay, a range of concentrations of the main components were tested with a capped and polyadenylated mRNA expressing the bacterial enzyme Chloramphenicol Acetyltransferase (CAT). Translational efficiency is judged by the amount of the CAT protein (ng) measured by a colorimetric enzyme immunoassay (CAT ELISA, Böhringer Mannheim).
- 25 Two sets of transcripts coding for the reporter enzymes CAT (Preiss. T. & Hentze. M. W. 1998 Nature 392:516-520) and firefly luciferase. Luc, (Iizuka. N. et al. 1994 Mol. Cell. Biol. 14:7322-7330) were tested in the translation assay and the functional half life of each transcript has been determined to be as follows:
 - 5' capped (Cap, m7Gppp) 40 minutes

- 5' capped and polyadenylated (pA, 98 adenines) 55 minutes
- uncapped <10 minutes
- uncapped and polyadenylated <10 minutes

Figure 8 shows a northern blot analysis of the transcripts during the translation assay.

- 5 Bars represent radioactive intensity of each messenger measured by a phosphoimager. Graph (A) shows the four messengers at different times, from 0 to 150 min. Graph (B) shows the Cap and the Cap-pA transcripts from 0 to 90 min.

The efficiency of translation of capped mRNAs having a polyA tail is thus remarkably higher than the one lacking it. Using several batches of CAT transcripts, it has been

- 10 observed that differences between capped and capped-polyadenylated messengers are in a range of 15 to 60 fold. Uncapped mRNA are poorly translated and are also rapidly degraded.

In order to study the PolyA effect independently from the presence of the Cap, the stability of the Luc transcripts was enhanced using the cap structure analog

- 15 G(5')ppp(5')A (Acap).

Figure 9 shows the time course of translation of the Luc messengers. Efficiency of translation is represented by light emission measured by a luminometer. Graph (B) shows the data represented in graph (A) with the y axis maximum at 20000 luminescence instead of 550000.

- 20 The functional half life of each transcript has been determined to be :

- Cap: 40 minutes
 - Cap and pA: 40 minutes
 - Acap: 25 minutes
 - Acap and pA: 60 minutes
- 25
- uncapped: 12 minutes
 - uncapped and pA: 20 minutes

The synergism of the polyA and the Cap structures is shown by the 40 fold difference of translation of the Cap-pA mRNA with respect to the sum of the translation of the two mRNAs Cap and Acap-pA.

References

Becker PB, Tsukiyama T and Wu C (1994). Chromatin assembly extracts from *Drosophila* embryos. *Methods Cell Biol.* 44:207-23.

Scott, M. P., Storti, R. V., Pardue, M. L. and Rich A. (1979) Cell-free protein synthesis
5 in lysates of *Drosophila melanogaster* cells. *Biochem.* 18: 1588-1594.

CLAIMS

1. A method for the *in vitro* translation of a ribonucleic acid template, said ribonucleic acid having both a 5' cap and a 3' poly A tail, said method comprising incubating a cell
5 extract of a multicellular eukaryote with said ribonucleic acid template under conditions such that translation of the RNA template to produce its encoded protein by one or more components in the cell extract occurs and the amount of the encoded protein thus produced is greater than the total of (a) the amount of the encoded protein that is produced under said conditions when the ribonucleic acid template has a 5' cap but no
0 3' poly A tail, plus (b) the amount of the encoded protein that is produced under said conditions when the ribonucleic acid template has a 3' poly A tail but no 5' cap.
2. The method according to claim 1 wherein the cell extract is an animal cell extract.
- 5 3. The method according to claim 2 wherein the cell extract is a mammalian cell extract.
4. The method according to claim 3 wherein the cell extract is a human cell extract.
5. The method according to claim 2 wherein the cell extract is an insect cell extract.
- 0 6. The method according to claim 5 wherein the cell extract is a *Drosophila* cell extract.
7. The method according to claim 6 wherein the cell extract is a *Drosophila* embryo cell
extract.
- 5 8. The method according to claim 7 wherein the *Drosophila* embryo cell extract is prepared by a method comprising dechorionating *Drosophila* embryos in an aqueous isotonic buffer comprising detergent and bleach.
- 0 9. The method according to claim 8 wherein the detergent is Triton X-100 and the bleach is sodium hypochlorite.

10. The method according to either of claims 8 or 9 which further comprises after dechorionating, the steps of washing the embryos; homogenizing the embryos to produce a homogenate; centrifuging the homogenate; and recovering non-pelleted material from the centrifuged homogenate.
- 5
11. The method according to claim 6 wherein the cell extract is a *Drosophila* ovary cell extract.
12. The method according to claim 11 wherein the *Drosophila* ovary cell extract is prepared
0 by a method comprising (a) obtaining *Drosophila* ovaries in isotonic medium; (b) washing the ovaries so as to transfer the ovaries slowly from isotonic medium to hypotonic medium, such that the volume of the ovaries increases; (c) homogenising the ovaries to produce a homogenate; (d) centrifuging the homogenate to form an ovary cell extract; and (e) recovering non-pelleted material from the centrifuged homogenate.
- 5
13. The method according to any one of the preceding claims wherein said conditions comprise the presence of the following: creatine phosphate, creatine kinase, potassium and magnesium salts, spermidine, amino acids, a reducing agent, and tRNA.
- 0 14. The method according to any one of the preceding claims wherein said conditions comprise a temperature in the range of 18° to 37°C, and said incubating is for at least 90 minutes.
15. The method according to any one of the preceding claims wherein said incubating is at
.5 25°C.
16. A method for the preparation of a *Drosophila* embryo extract comprising:
- a) dechorionating *Drosophila* embryos in an aqueous isotonic buffer comprising detergent and bleach;
- 10 b) washing the embryos;
- c) homogenizing the embryos to produce a homogenate;
- d) centrifuging the homogenate; and
- e) recovering non-pelleted material from the centrifuged homogenate.

17. A method for the preparation of a *Drosophila* ovary cell extract comprising (a) obtaining *Drosophila* ovaries in isotonic medium comprising detergent and bleach; (b) washing the ovaries so as to transfer the ovaries slowly from isotonic medium to hypotonic medium, such that the volume of the ovaries increases; (c) homogenising the ovaries to produce a homogenate; (d) centrifuging the homogenate to form an ovary cell extract; and (e) recovering non-pelleted material from the centrifuged homogenate.
18. A method according to either of claims 16 or 17, wherein said detergent is non-ionic.
19. A method according to any one of claims 16-18, wherein said homogenising is performed in the presence of protease inhibitors.
20. A method according to any one of claims 16-19 wherein said buffer is EW buffer (0.7% NaCl, 0.4% Triton X-100).
21. A method according to any one of claims 16-20, wherein said embryos or ovaries are incubated in said isotonic buffer for between 1 and 9 minutes.
22. A method according to claim 21, wherein said embryos or ovaries are incubated for about 3 minutes.
23. A method according to any one of claims 16-22, wherein said embryos or ovaries are incubated at between 18 and 37°C.
24. A method according to claim 23, wherein said embryos or ovaries are incubated at about 25°C.
25. A method according to any one of claims 16-24 wherein said embryos or ovaries are homogenised at about 4°C.
26. A method according to any one of claims 16-25 additionally comprising the step of adding glycerol to the recovered non-pelleted material to a concentration of about 10% by volume.
27. A method for the preparation of a mammalian cell extract comprising the steps of a) collecting cells by centrifugation; b) washing the cells; c) resuspending the cells; d)

homogenising the cells to produce a homogenate; e) centrifuging the homogenate and f) recovering non-pelleted material from the centrifuged homogenate.

28. A method for the *in vitro* translation of a ribonucleic acid template, said method comprising the steps of:

- 5 a) adding a ribonucleic acid template to a translation mix in the presence of an embryo extract produced by the method of any one of claims 16-26, an ovary cell extract produced by a method according to any one of claims 17-26, or a mammalian cell extract produced by the method of claim 27 to form a reaction mix,
- b) incubating the reaction mix for at least 90 minutes.

10 29. A method according to claim 28, wherein said reaction mix comprises spermidine, amino acids, creatine phosphate, creatine kinase, dithiothreitol (DTT), buffer, $Mg(OAc)_2$, KOAc, tRNA, embryo or cell extract, and RNA template.

30. A method according to claim 29, wherein said buffer is hypotonic buffer (10mM HEPES pH7.4, 5mM DTT).

5 31. A method according to either of claims 29 or 30, wherein said tRNA is calf liver tRNA.

32. A method according to any of claims 29-31, wherein the concentrations of the components of said reaction mix are as follows: spermidine, about 0.1mM; amino acids, about 60 μ M; DTT, 0-4mM; creatine phosphate, 17-23mM; creatine kinase, 0.08mg/ml; buffer, about 24mM; $Mg(OAc)_2$, 0-3mM; KOAc, 0-200mM; calf liver tRNA, 0-150 μ g/ml; embryo or cell extract, about 40% and RNA template, 1-3ng/ μ l.

0

33. A method according to claim 32, wherein the components of said reaction mix are as follows: spermidine, 0.1mM; amino acids, 60 μ M; DTT, 0-4mM; creatine phosphate, 17-23mM; creatine kinase, 0.08mg/ml; HEPES buffer, 24mM; $Mg(OAc)_2$, 0-3mM; KOAc, 60mM; calf liver tRNA, 100 μ g/ml; embryo or cell extract, 40% and RNA template, 3.2ng/ μ l.

5

34. A method according to any one of claims 28-33, wherein said reaction mix is prepared fresh.

35. A method according to any one of claims 29-34, wherein said creatine phosphate is prepared fresh or is newly thawed.
36. The method according to any one of claims 28-35 wherein said ribonucleic acid template is capped and contains a poly A tail of at least 30 adenine nucleotides in length.
37. A *Drosophila* embryo cell extract, ovary cell extract or mammalian cell extract produced by the method of any one of claims 16-27.
38. Use of embryo or cell extract according to claim 37 in a method of *in vitro* translation of a ribonucleic acid template.
39. A method according to any one of claims 1-15 wherein said cell extract is prepared according to the method of any one of claims 16 to 27.
40. A method of identifying a candidate molecule that increases or decreases the amount of a produced translation product, comprising:
- a) performing the method according to any one of claims 1-15, 28-36 or 39 wherein said conditions or reaction mix comprise the presence of one or more candidate molecules being screened for the ability to increase or decrease the amount of the encoded protein that is produced; and
 - b) identifying any one or more candidate molecules that increase or decrease the amount of the encoded protein that is produced relative to the amount of the encoded protein that is produced in the absence of the one or more candidate molecules.
41. A purified candidate molecule that is identified according to the method of claim 40.
42. A kit for *in vitro* translation of ribonucleic acid comprising the following ingredients: spermidine, amino acids, creatine phosphate, creatine kinase, optionally dithiothreitol, buffer, $\text{Mg}(\text{OAc})_2$, KOAc, tRNA, *Drosophila* or mammalian cell extract according to claim 37, and RNA template.
43. A kit according to claim 42, wherein said buffer is HEPES buffer.

44. A kit according to either of claims 42 or 43, wherein said tRNA is calf liver tRNA.

09/914149

1/10

FIG. 1**Experiment E-872 Blow up (one set of data eliminated)**

c = cap, a = poly(A), c-a = cap and poly(A)

Synergism = fold over the sum of c+a value






FIG. 2


Experiment E-872

c = cap, a = poly(A), c-a = cap and poly(A)
Synergism = fold over the sum of c+a value



3/10
FIG. 3

- Luc RNA FROM PROMEGA
- FOR c-luc-a OPTIMAL IS ALSO 0.3mM (THOMAS' DATA)


FIG. 5

- Luc RNA FROM PROMEGA
- MERGE OF 2 \neq EXP

SUBSTITUTE SHEET (RULE 26)


4/10

FIG. 4



- Luc RNA FROM PROMEGA
- FOR c-luc-a RNA OPTIMAL IS 40mM (THOMAS' DATA)
- MERGE OF 2 \neq EXP.

FIG. 6



- Luc RNA FROM PROMEGA

5/10

FIG. 7





FIG. 8

E876
c-Luc-a RNA

6/10





FIG. 9

7/10

FIG. 10


E876

c-luc-a RNA



8/10

FIG. 11



9/10

FIG. 12A





FIG. 12B



10/10

FIG. 13A





FIG. 13B



Declaration and Power of Attorney for Patent Application English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"TRANSLATION SYSTEM"

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on August 22, 2001 as United States Application No. 09/914,149

and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			<u>Priority Not Claimed</u>
9904004.0 (Number)	Great Britain (Country)	Feb. 22, 1999 (Day/Month/Year Filed)	<input type="checkbox"/>
9919369.0 (Number)	Great Britain (Country)	Aug. 16, 1999 (Day/Month/Year Filed)	<input type="checkbox"/>
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/>

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)
_____ (Application Serial No.)	_____ (Filing Date)

I hereby claim the benefit under 35 U.S.C. Section 120 of the United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark office all information known to me to be material to patentability as defined in Title 37, C.F.C., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

PCT/IB00/00219 _____ (Application Serial No.)	February 22, 2000 _____ (Filing Date)	_____ (Status) (patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	_____ (Status) (patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

0991449-121901

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

David G. Conlin	Reg. No. 27,026	William J. Daley, Jr.	Reg. No. 35,487
Kathryn A. Piffat, Ph.D.	Reg. No. 34,901	Cara Z. Lowen	Reg. No. 38,227
Christine C. O'Day	Reg. No. 38,256	George W. Neuner	Reg. No. 26,964
Robert L. Buchanan	Reg. No. 40,927	David E. Tucker	Reg. No. 27,840
Linda M. Buckley	Reg. No. 31,003	George W. Hartnell, III	Reg. No. 42,368
Peter J. Manus	Reg. No. 26,766	Lisa Swisocz Hazzard	Reg. No. 44,368
John B. Alexander	Reg. No. P-48,399	Peter F. Corless	Reg. No. 33,860
Steven M. Jensen	Reg. No. 42,693	Richard Roos	Reg. No. 45,053

Send Correspondence to:

David G. Conlin, Esq.
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, Massachusetts 02209
U.S.A.

Direct Telephone Calls to:
(name and telephone number)

David G. Conlin
Telephone: (617) 439-4444
Facsimile: (617) 439-4170

Full name of sole or first inventor FATIMA GEBAUER	
Sole or first inventor's signature	Date:
Residence GERMANY	
Citizenship GERMAN	
Post Office Address Lerchenstrasse 28, D-69251 Gailberg, Germany	

106111 5441660

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

David G. Conlin	Reg. No. 27,026	William J. Daley, Jr.	Reg. No. 35,487
Kathryn A. Piffat, Ph.D.	Reg. No. 34,901	Cara Z. Lowen	Reg. No. 38,227
Christine C. O'Day	Reg. No. 38,256	George W. Neuner	Reg. No. 26,964
Robert L. Buchanan	Reg. No. 40,927	David E. Tucker	Reg. No. 27,840
Linda M. Buckley	Reg. No. 31,003	George W. Hartnell, III	Reg. No. 42,368
Peter J. Manus	Reg. No. 26,766	Lisa Swisocz Hazzard	Reg. No. 44,368
John B. Alexander	Reg. No. P-48,399	Peter F. Corless	Reg. No. 33,860
Steven M. Jensen	Reg. No. 42,693	Richard Roos	Reg. No. 45,053

Send Correspondence to:

David G. Conlin, Esq.
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, Massachusetts 02209
U.S.A.

Direct Telephone Calls to:
(name and telephone number)

David G. Conlin
Telephone: (617) 439-4444
Facsimile: (617) 439-4170

Full name of sole or first inventor FATIMA GEBAUER	
Sole or first inventor's signature	Date:
Residence GERMANY	
Citizenship GERMAN	
Post Office Address Lerchenstrasse 28, D-69251 Gailberg, Germany	

TOP SECRET

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

David G. Conlin Reg. No. 27,026
 Kathryn A. Piffat, Ph.D. Reg. No. 34,901
 Christine C. O'Day Reg. No. 38,256
 Robert L. Buchanan Reg. No. 40,927
 Linda M. Buckley Reg. No. 31,003
 Peter J. Manus Reg. No. 26,766
 John B. Alexander Reg. No. P-48,399
 Steven M. Jensen Reg. No. 42,693

William J. Daley, Jr. Reg. No. 35,487
 Cara Z. Lowen Reg. No. 38,227
 George W. Neuner Reg. No. 26,964
 David E. Tucker Reg. No. 27,840
 George W. Hartnell, III Reg. No. 42,368
 Lisa Swiszc Hazzard Reg. No. 44,368
 Peter F. Corless Reg. No. 33,860
 Richard Roos Reg. No. 45,053

Send Correspondence to:

David G. Conlin, Esq.
 Dike, Bronstein, Roberts & Cushman
 Intellectual Property Practice Group of
 EDWARDS & ANGELL, LLP
 P.O. Box 9169
 Boston, Massachusetts 02209
 U.S.A.

Direct Telephone Calls to:
(name and telephone number)

David G. Conlin
 Telephone: (617) 439-4444
 Facsimile: (617) 439-4170

Full name of sole or first inventor FATIMA GEBAUER	
Sole or first inventor's signature	Date:
Residence GERMANY	
Citizenship GERMAN	
Post Office Address Lerchenstrasse 28, D-69251 Gailberg, Germany	


106121 5444660

16

William J. Daley, Jr.	Reg. No. <u>35,487</u>
Cara Z. Lowen	Reg. No. <u>38,227</u>
George W. Neuner	Reg. No. <u>26,964</u>
David E. Tucker	Reg. No. <u>27,840</u>
George W. Hartnell, III	Reg. No. <u>42,368</u>
Lisa Swiszc Hazzard	Reg. No. <u>44,368</u>
Peter F. Corless	Reg. No. <u>33,860</u>
Richard Roos	Reg. No. <u>45,053</u>

David G. Conlin, Esq.
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group of
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, Massachusetts 02209
U.S.A.

David G. Conlin
Telephone: (617) 439-4444
Facsimile: (617) 439-4170

Full name of sole or first inventor FATIMA GEBAUER	
Sole or first inventor's signature 	Date: 9-10-01
Residence GERMANY	
Citizenship GERMAN SPANISH	
Post Office Address Lerchenstrasse 28, D-69251 <u>Gailberg</u> , Germany DEX	

2-00
Full name of second inventor, if any
Davide Corona

Second inventor's signature

Date:

9-10-2001

Residence
GERMANY

U.S.A. (D.C.)

Citizenship
German

ITALIANA (D.C.)

Post Office Address

~~Brechtelstrasse 8-10, D-69126 Heidelberg, Germany~~ CA (D.C.)
125 PEACH TERRACE, SANTA CRUZ - CA, 95060 (U.S.A.)

Full name of third inventor, if any
Giovanna Bergamini

Third inventor's signature

Date:

Residence
GERMANY

Citizenship
German

Post Office Address

Römerstrasse 25, D-69115 Heidelberg, Germany

Full name of third inventor, if any
Peter Becker

Third inventor's signature

Date:

Residence
GERMANY

Citizenship
German

Post Office Address

Salzstrasse 9, D-82194 Gröbenzell, Germany

TELETYPE

Full name of second inventor, if any Davide Corona	
Second inventor's signature	Date:
Residence GERMANY	
Citizenship German	
Post Office Address Brechtelstrasse 8-10, D-69126 Heidelberg, Germany	

Full name of third inventor, if any Giovanna Bergamini	
Third inventor's signature	Date:
Residence GERMANY	
Citizenship German	
Post Office Address Römerstrasse 25, D-69115 Heidelberg, Germany	


Full name of third inventor, if any Peter Becker	
Third inventor's signature	Date:
Residence GERMANY	
Citizenship German	
Post Office Address Salzstrasse 9, D-82194 Gröbenzell, Germany	

T06121 6411660

Full name of second inventor, if any Davide Corona	
Second inventor's signature	Date:
Residence GERMANY	
Citizenship German	
Post Office Address Brechtelstrasse 8-10, D-69126 Heidelberg, Germany	

Full name of third inventor, if any Giovanna Bergamini	
Third inventor's signature	Date:
Residence GERMANY	
Citizenship German	
Post Office Address Römerstrasse 25, D-69115 Heidelberg, Germany	

400

Full name of third inventor, if any Peter Becker	
Third inventor's signature 	Date: 14.10.2007
Residence GERMANY	
Citizenship German	
Post Office Address Salzstrasse 9, D-82194 Gröbenzell, Germany DER	

Full name of second inventor, if any Davide Corona	
Second inventor's signature	Date:
Residence GERMANY	
Citizenship German	
Post Office Address Brechtelstrasse 8-10, D-69126 Heidelberg, Germany	

300


Full name of third inventor, if any Giovanna Bergamini	
Third inventor's signature <i>Giovanna Bergamini</i>	Date: 10-10-01
Residence GERMANY	
Citizenship German ITALIAN	
Post Office Address Römerstrasse 25, D-69115 Heidelberg, Germany MÖNCHHOFSTRASSE 32, D-69120 HEIDELBERG, GERMANY DEK	

Full name of third inventor, if any Peter Becker	
Third inventor's signature	Date:
Residence GERMANY	
Citizenship German	
Post Office Address Salzstrasse 9, D-82194 Gröbenzell, Germany	

106444660

500
Full name of third inventor, if any
Matthias Hentze

Third inventor's signature



Date:

9 October 2001

Residence

GERMANY

Citizenship

German

Post Office Address

Merianstrasse 5, D-69117 Heidelberg, Germany *DER*

1005121 6441550

ASSIGNMENT

WHEREAS, the following inventor(s): **Fatima Gebauer, Davide Corona, Giovanna Bergamini, Peter Becker and Matthias Hentze**, hereinafter designated as the undersigned) have invented certain new and useful improvements in "**TRANSLATION SYSTEM**" for which **PCT** application for Letters Patent of the United States has been filed on **August 22, 2001**, and assigned Serial No. **09/914,149**; and

WHEREAS, **Whatman, Inc.**, a **Massachusetts** corporation, having its principal place of business at **200 Wells Avenue, Newton, Massachusetts 02459-3304** its heirs, successors, legal representatives and assigns (hereinafter designated as the Assignee) is desirous of acquiring the entire right, title and interest in and to said invention and to any Letters Patent(s) that may be granted therefore in the United States of America;

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) and other good and valuable consideration to the undersigned, the receipt of which is hereby acknowledged, the undersigned have sold, assigned and transferred, and by these presents do sell, assign and transfer unto said Assignee the full and exclusive right to the said invention in the United States of America and its territories, dependencies and possessions and the entire right, title and interest in and to any and all Letters Patent(s) which may be granted therefore in the United States of America and its territories, dependencies and possessions, and in and to any and all divisions, reissues, continuations and extensions thereof for the full term or terms for which the same may be granted.

The undersigned agree to execute all papers necessary in connection with this application and any continuing, divisional or reissue applications thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient, including any related foreign and international applications.

The undersigned agree to furnish all pertinent facts and documents relating to said application, said invention and said patent(s) as may be known and accessible to the undersigned, and will testify as to the same in any interference or litigation related thereto, and will promptly execute and deliver to Assignee any and all papers, instruments or affidavits necessary or desirable to apply for, obtain, maintain or enforce said application or said patent(s) in connection with any interference which may be declared, and any litigation concerning this application or any continuation, division or reissue thereof or Patent(s) or reissue patent(s) issued thereon, and to cooperate with the Assignee in every way possible in obtaining and producing evidence and proceeding with such interference or litigation.

The undersigned agree to execute all papers and documents and to perform any act, which may be necessary in connection with claims or provisions of the International Convention for the Protection of Industrial Property or similar agreements.

The undersigned agree to perform all affirmative acts which may be necessary to obtain a grant of a valid United States patent(s) to the Assignee and to vest all rights therein hereby conveyed to said Assignee as fully and entirely as the same would have been held by the undersigned if this Assignment and sale had not been made.

09914149